Subscribe to RSS
DOI: 10.1055/s-0037-1615397
The Effects of MPL-Ligand, Interleukin-6 and Interleukin-11 on Megakaryocyte and Platelet Alpha-granule Proteins
Publication History
Received
13 February 1998
Accepted after resubmission
02 September 1998
Publication Date:
07 December 2017 (online)
Summary
Thrombopoietin (Mpl ligand), interleukin-6 (IL-6), and interleukin-11 (IL-11) differ in their effects on megakaryocyte maturation and development. In the present study, the impact of these thrombocytopoietic cytokines on biochemical and structural granule and membrane components was examined. Western blotting was performed on equivalent amounts of isolated megakaryocyte or platelet protein and the relative intensities of the enhanced chemiluminescent-visualized bands were quantitated by densitometry. Megakaryocyte growth and development factor (MGDF), a recombinant thrombopoietin-related molecule, significantly increased megakaryocyte fibronectin (72%), thrombospondin (55%), von Willebrand factor (28%) and p-selectin (CD62p) (37%) when compared to equivalent amounts of protein from saline-treated controls (p < 0.01). Megakaryocyte fibrinogen was not increased. Ultrastructurally, there was a marked increase in ribosomes and rough endoplasmic reticulum even in mature-appearing megakaryocytes. Platelets from MGDF-treated mice showed small increases in fibronectin (8%), and CD62p (18%), but did not show increases in other measured α-granule proteins. Neither IL-6 nor IL-11 increased megakaryocyte or platelet α-granule proteins over levels observed in saline controls. IL-11 treated megakaryocytes, while also exhibiting an increase in ribosomes, were characterized by prominent cytoplasmic fragmentation. The study demonstrates the impact of Mpl ligand in increasing synthesized megakaryocyte α-granule proteins and of IL-11 in promoting megakaryocyte fragmentation.
-
References
- 1 Burstein SA, Mel RL, Henthom J, Friese P, Turner K. Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol 1992; 153: 305-12.
- 2 Neben TY, Loebelenz J, Hayes L, McCarthy K, Stoudemire J, Schaub R, Goldman SJ. Recombinant interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 1993; 81: 901-8.
- 3 Bruno E, Bridel RA, Cooper RJ, Hoffman R. Effect of recombinant inter-leukin-11 on human megakaryocyte progenitor cells. Exp Hematol 1991; 19: 378-81.
- 4 Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y. Interleukin 6 is a potent thrombopoietic factor in vivo in mice. Blood 1989; 74: 1241-4.
- 5 Hill RJ, Warren MK, Levin J. Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. J Clin Invest 1990; 85: 1242-7.
- 6 Stahl CP, Zucker-Franklin D, Evatt BL, Winton EF. Effects of human interleukin-6 on megakaryocyte development and thrombocytopoiesis in primates. Blood 1991; 78: 1467-75.
- 7 Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Ort PJ, Hagen FS, Roth GJ, Papayannopoulou T, Foster DC. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568-71.
- 8 Debili N, Wendling F, Katz A, Guichard J, Breton-Gorius J, Hunt P, Vainchenker W. The Mpl ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995; 86: 2516-25.
- 9 Zeigler FC, De Sauvage FJ, Widmer HR, Keller GA, Donahue C, Schreiber RD, Malloy B, Hass P, Eaton D, Matthews W. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994; 84: 4045-52.
- 10 Arnold JT, Daw NC, Stenberg PE, Jayawardene D, Srivastava DK, Jackson CW. A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size, and ploidization. Blood 1997; 89: 823-33.
- 11 Jackson CW, Huston NK, Steward SA, Saito N, Cramer EM. Platelets of the Wistar Furth rat have reduced levels of alpha-granule proteins. J Clin Invest 1991; 87: 1985-91.
- 12 Gerrard JM, Phillips DR, Rao GH, Plow EF, Walz DA, Ross R, Harker LA, White JG. Biochemical studies of two patients with the gray platelet syndrome. Selected deficiency of platelet alpha granules. J Clin Invest 1980; 66: 102-9.
- 13 Nurden AT, Kunick TJ, Dupuis D, Soria C, Caen JP. Specific protein and glycoprotein deficiencies in platelets isolated from two patients with the gray platelet syndrome. Blood 1982; 59: 709-18.
- 14 White JG. Ultrastructural studies of the gray platelet syndrome. Am J Pathol 1979; 95: 445-62.
- 15 Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier Syndrome. Blood 1998; 91: 4397-418.
- 16 Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Saris C, Orkin SH. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1985; 81: 695-704.
- 17 Cramer EM, Debili N, Martin JF, Gladwin A-M, Breton-Gorius J, Harrison P, Savidge GF, Vainchenker W. Uncoordinated expression of fibrinogen compared with thrombospondin and von Willebrand factor in maturing human megakaryocytes. Blood 1989; 73: 1123-9.
- 18 Schick PK, Wojenski CM, Bennett VD, Ivanova T. The synthesis and localization of alternatively spliced fibronectin EIIIB in resting and thrombin-treated megakaryocytes. Blood 1996; 87: 1817-23.
- 19 Berman CL, Yeo EL, Wencel-Drake J, Furie BC, Ginsberg ML, Furie B. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation: characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. J Clin Invest 1986; 78: 130-7.
- 20 Heijnen H, Debili N, Vainchenker W, Breton-Gorius J, Geuze HJ, Sixma JJ. Multivesicular bodies are an intermediate stage in the formation of platelet α-granules. Blood 1998; 91: 2313-25.
- 21 Handagama PJ, Shuman MA, Bainton DF. Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules. J Clin Invest 1989; 84: 73-82.
- 22 Kaushansky K, Broudy VC, Lin N, Jorgensen M, McCarty J, Fox N, Zucker-Franklin D, Lofton-Day C. Thrombopoietin, the Mpl-ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995; 92: 3234-8.
- 23 Zucker-Franklin D, Kaushansky K. Effect of thrombopoietin on the development of megakaryocytes and platelets: an ultrastructural analysis. Blood 1996; 88: 1632-8.
- 24 Cramer EM, Norol F, Guichard J, Greton-Gorius J, Vainchenker W, Masse J-M, Debili N. Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. Blood 1997; 89: 2336-46.
- 25 Kaviani MD, Mason LE, Bree AG, Nagle SL, Schlerman FJ, Donnelly LH, Schaub RG, Zucker-Franklin D, Goldman SJ. Effects of recombinant human interleukin 11 on the activation and morphology of peripheral blood platelets and megakaryocytes in nonhuman primates. Blood 1996; 88: 26a (abstr)
- 26 Fanucchi M, Glaspy J, Crawford J, Garst J, Figun R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336: 404-9.
- 27 Ulich TR, del Castillo J, Senaldi G, Kinstler O, Yin S, Kaufman S, Tarpley J, Choi E, Kirley T, Hunt P, Sheridan WP. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996; 87: 5006-15.
- 28 Stahl CP, Winton EF, Monroe MC, Holman RC, Zelasky M, Liehl E, Myers LA, McClure H, Anderson D, Evatt BL. Recombinant human granulocyte-macrophage colony-stimulating factor promotes megakaryocyte maturation in nonhuman primates. Exp Hemat 1991; 19: 810-6.
- 29 Leven RM, Rodriguez A. Immunomagnetic bead isolation of megakaryocytes from guinea-pig bone marrow: effect of recombinant interleukin-6 on size, ploidy and cytoplasmic fragmentation. Br J Hematol 1991; 77: 267-73.
- 30 An E, Ogata K, Kuriya S, Nomura T. Interleukin-6 and erythropoietin act as direct potentiators and inducers of in vitro cytoplasmic process formation on purified mouse megakaryocytes. Exp Hemat 1994; 22: 144-56.
- 31 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
- 32 Laemmli UK. Cleavage of structural proteins during assembly of the head of the bacteriophage T4. Nature 1970; 227: 680-5.
- 33 Bouma H, Fuller GM. Partial chemical characterization of rat fibrinogen. J Biol Chem 1975; 250: 4678-83.
- 34 Stahl CP, Zucker-Franklin D, McDonald TP. Incomplete antigenic cross-reactivity between platelets and megakaryocytes: relevance to ITP. Blood 1986; 67: 421-8.
- 35 Zucker-Franklin D, Petursson S. Thrombocytopoiesis-analysis by membrane tracer and freeze-fracture studies on fresh human and cultured mouse megakaryocytes. J Cell Biol 1984; 99: 390-402.
- 36 Heilmann E, Hynes LA, Friese P, George N, Burstein SA, Dale GL. Dog platelets accumulate intracellular fibrinogen as they age. J Cell Physiol 1994; 161: 23-30.
- 37 Handagama PJ, Amrani DL, Shuman MA. Endocytosis of fibrinogen into hamster megakaryocyte alpha granules is dependent on a dimeric gamma A configuration. Blood 1995; 85: 1790-5.
- 38 Kieffer N, Guichard J, Farcet J-P, Vainchenker W, Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987; 164: 189-95.
- 39 Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88: 511-21.